个人简介：

Dr. Ying is the inventor of Ranok’s innovative targeted protein degradation technology. He was most recently Co-founder and President of the immuno-oncology startup Capten Therapeutics and brings to Ranok over 19 years’ industry experience in medicinal chemistry, drug discovery, preclinical and clinical development. Previously, he was Vice President of Discovery Chemistry at Synta Pharmaceuticals and was responsible for creating a program in protein homeostasis that resulted in advancing the HSP90 inhibitor ganetespib from discovery to Phase 3. He also conceived Synta’s novel tumor-targeted drug conjugate technology, which was out-licensed to Tarveda Therapeutics for up to $249M USD. Dr. Ying was a post-doctoral fellow in Biophysics at Yale University and State University of New York at Stony Brook and received his Ph.D. and MS degrees in Organic Chemistry at Clemson University and Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences.

公司简介：

Ranok is a privately held, pre-clinical stage biopharmaceutical company that is pioneering an innovative targeted protein degradation technology for the discovery and development of novel therapeutics. Ranok was founded by a leadership team of industry veterans from both Chinese and American biotech and pharmaceutical companies and is based in two of the world’s leading centers of innovation and medical research: Hangzhou, China and Boston, Massachusetts USA. By bringing together the cutting edges of medical research from both China and the United States, our goal is to create transformative medicines for patients suffering from cancer and other serious diseases.